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brain tumors
Aleksandar Stojsavljević1,2*, Ljiljana Vujotić3,4, Branislav Rovčanin3,5, Slavica Borković-Mitić6, 
Marija Gavrović-Jankulović2 & Dragan Manojlović2
The pathogenesis of malignant brain tumors (MBTs) should be better understood due to the evident 
association between prolonged exposure to metals and increased risk of MBTs. The present research 
aimed to find trace metals that could contribute to the pathogenesis of MBTs. Essential trace 
elements (Mn, Co, Zn, Cu, Se) and relevant toxic metals (Al, Ni, As, Sr, Cd, Ce, Pt, Pb, U) in the serum, 
cell fraction (CF), cerebrospinal fluid (CSF) and cancerous tissue (CT) samples of MBT patients were 
analyzed. The results were compared with sex- and age-matched control groups. For the first time, 
this research showed that elemental profiles of serum, CF, CSF and CT samples in MBT patients were 
significantly altered compared to the appropriate controls, as well as that higher contents of trace 
elements (particularly Mn, Se, and Pb) could be involved in the pathogenesis of MBTs. However, the 
most noticeable change found was the elevated U content, indicating its considerable role as a major 
cerebral discriminator of the presence/absence of MBTs. The U/Se ratio could be considered as an 
appropriate blood marker in diagnostic MBT evaluation. The reported results could contribute to better 
understanding of the poorly understood pathogenesis of MBTs. Furthermore, the reported results could 
highlight a molecular basis for the pathophysiological changes caused by the hazardous effects of trace 
metals on brain homeostasis.
The importance of trace metals in the neurosciences has become more compelling during the first decade of the 
21st century1, as there is considerable interest in finding the relationships between trace metals and various neu-
rological diseases, including central nervous system (CNS) malignancies. Metals show their harmful effects at the 
first stage of cancerogenesis (initiation)2. Initiation can affect normal biochemical reactions, leading to alterations 
in metal profiles. Considering that trace metals play a significant role in neoplastic processes, the metal con-
tents in neoplastic samples can differ from the composition in control ones3. Homeostasis of metals within tight 
physiological limits is maintained through the mechanisms of uptake, distribution, accumulation, and secretion. 
Each breakdown has deleterious effects on metal-regulated metabolic pathways and can be a crucial step in the 
pathogenesis of various diseases. The most important pathway in metal-induced cancerogenesis is the ability of a 
metal to modulate gene expression by interfering with signal transduction pathways, leading to the deregulation 
of cell proliferation, activation of numerous transcription factors, disruption of cell cycle course, and apoptosis4.
Metal homeostasis is critical for the proper functioning of the brain5. The brain is a target organ for toxic envi-
ronmental pollutants6. The balance of metals within the brain is regulated through the blood-brain barrier (BBB) 
and blood-cerebrospinal fluid (CSF) barrier. In physiological conditions, these barriers regulate CNS homeostasis 
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and protect the CNS against hazardous chemicals. Damage to the endothelial structure of the BBB is a major 
cause of metal leakage into the surrounding brain parenchyma7. Based on metals’ abilities to pass through the 
BBB, it was hypothesized that prolonged exposure to metals could increase the risk of brain cancers, although no 
association between metal exposure and brain cancer was found8.
Primary malignant CNS tumors comprise 1.4% of all human cancers9. However, they are among the most 
lethal forms of human cancers due to their aggressive clinical evolution. The reported mortality rate of primary 
CNS tumors is approximately 60% in the first five years and they are ranked sixth among all malignancies9–11. 
Brain cancers are most frequently diagnosed in men, particularly the elderly10. The most common types of 
malignant brain tumors (MBTs) are gliomas, comprising approximately 80% of all primary brain neoplasms12–14. 
Glioblastomas are the most frequent and the most aggressive intraparenchymal MBTs in the adult population15.
Although metal analysis of liquid clinical samples cannot determine the role of metals in the pathogenesis 
of diseases, measurement of metals in serum, CSF, and other liquid samples can provide information related to 
metal deregulation in various diseases16. Analysis of trace metals in CNS tissues is the exact means to highlight 
the role of metals in the pathogenesis of neurological diseases. However, collecting brain tissues is difficult and 
feasible only after autopsy or surgery, considering that brain biopsy procedures are performed for histopatholog-
ical examination of tumors in the diagnosis of cancer5. This could explain the insufficient number of studies in 
which metallomics has been utilized at the level of brain tissues.
The main objectives of this research were to assess whether trace metals could contribute to the pathogenesis 
of MBTs, and to examine if any of the selected metal ratios could be considered as a potential blood marker in the 
diagnostic evaluation of MBTs. In addition to its clinical relevance, the role of metal contaminants in the environ-
ment is also briefly discussed. In order to investigate metal profiles in the most representative way, various types 
of clinical samples were analyzed.
Results
The contents of metals in the analyzed samples are presented as mean ± standard deviation (st. dev.) and median 
values (Table 1). According to sex and age, the Chi-squared test showed no statistically significant difference 
between analyzed groups (p > 0.05). Therefore, the serum and cell fraction (CF) samples from MBT patients 
were compared to samples from blood donors, while CSF samples from MBT patients were compared to CSF 
samples from the hydrocephalus patients. The carcinogenic tissues (CTs) of patients were compared to healthy 
tissues (HTs) of the same patients. In this way, the most reliable comparison between groups was made. The box 
plots are given in Fig. 1. According to the Kolmogorov Smirnov’s test, the results for the metal contents showed 
skewed distributions, so differences between two groups were examined by the Mann-Whitney U-test (Table 1).
The most abundant metal in all samples was zinc (Zn), while the least abundant metal was platinum (Pt). 
Between the examined groups, there was no significant difference for aluminum (Al), cobalt (Co), nickel (Ni), 
copper (Cu), and arsenic (As) in any of the analyzed sample types (p > 0.05). Compared to control groups (CGs), 
MBT patients had significantly higher manganese (Mn) contents in serum (10.77 ± 5.47 vs. 4.71 ± 2.85 ng/g), 
CF (7.55 ± 5.32 vs. 3.06 ± 1.90 ng/g) and CT samples (132 ± 113 vs. 78 ± 29 ng/g), as well as higher lead (Pb) 
content in serum (11.79 ± 4.44 vs. 4.34 ± 1.07 ng/g), CF (8.52 ± 5.60 vs. 3.99 ± 0.89 ng/g) and CT samples (155 ± 
120 vs. 49 ± 36 ng/g) (p < 0.05). Higher cadmium (Cd) content was found in the blood samples of MBT patients 
when compared to the CGs, i.e. in the serum (0.31 ± 0.27 vs. 0.02 ± 0.01 ng/g) and CF (0.31 ± 0.31 vs. 0.01 ± 
0.003 ng/g). However, compared to the CGs, the Cd content was significantly lower in CSF (0.12 ± 0.07 vs. 0.26 ± 
0.22 ng/g) and CT samples (6.71 ± 6.02 ng/g vs. 4.63 ± 4.77 ng/g) of MBT patients. In contrast, the contents of Zn, 
selenium (Se), strontium (Sr) and cerium (Ce) were significantly lower in the serum, CF and CSF samples (with 
the exception of Se and Ce in CSFs), but were significantly higher in the CT samples of MBT patients (p < 0.05). 
According to the median values, and in comparison with the CGs, the contents of Zn and Se were approximately 
1.5-fold and 2.0-fold lower in both blood sample types and CSF samples of MBT patients, as well as 1.3-fold and 
2.2-fold higher in the CT samples, respectively. The content of Sr was 2.2-, 3.5-, and 1.6-fold lower in the serum, 
CF and CSF samples of MBT patients in comparison to the CGs, respectively, as well as 2.9-fold higher in TC 
samples. The most significant metal that distinguished serum, CF, CSF and TC samples of MBT patients from the 
appropriate CGs was uranium (U). In general, the U content was up to 3.5-fold higher in all analyzed samples of 
MBT patients (p < 0.05) (Table 1 and Fig. 1) than in controls. According to Chi-squared test, the U contents in 
analyzed samples from patients in the different examined regions of Serbia did not differ significantly (Fig. 2).
The ratios between the metals that showed statistically significant differences, as well as the Cu/Zn ratio, were 
further investigated in order to find potential candidates that could distinguish each sample group, as well as to 
find an appropriate diagnostic marker for MBT patients. The results are presented in Table 2. The Cu/Zn ratio was 
unable to discriminate any of the sample types analyzed. The Zn/Mn and Pb/Mn ratios were significantly lower 
in the sera and CFs of MBT patients. The opposite results were obtained for Zn/Se and Pb/Se ratios (these were 
numerically higher in the sera and CFs of MBT patients), but there was no significance difference between groups 
(p > 0.05). For MBT patients, higher ratios of U/Mn and U/Se were able to discriminate the serum, CF, CSF 
and TC samples of MBT patients from those of the CGs, especially the higher ratio of U/Se in serum (P5-P95: 
0.42–21.25 vs. 0.10–2.97 pg/kg) and CF (P5-P95: 0.70–30.35 vs. 0.19–3.73 pg/kg; p < 0.05), respectively (Table 2).
Discussion
Comparative analysis. According to the results obtained, MBT patients had significantly altered metal con-
tent in serum, CF, CSF, and CT samples. Since relatively few papers on this topic have been published to the best 
of our knowledge, the possibility of providing adequate comparative analysis is limited. Arslan et al.12 reported 
higher contents of Cd, Mn, Pb and Zn, lower Cu content, and unchanged Co content in the serum of patients with 
malignant gliomas compared to that of healthy subjects. These data are in agreement with ours, with the excep-
tion of Zn. El-Yazigl et al.17 showed that the concentration ratio of malignant/control patients was 2.11 for Pb in 
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Serum CF CSF Tissues
Control Tumor Control Tumor Control Tumor HT CT
Al
mean 6.66 2.84 4.40 1.01 0.89 0.60 30.78 40.49
st.dev. 2.84 2.36 2.47 0.73 0.68 0.41 40.10 50.15
median 6.60 1.78 3.82 0.77 0.70 0.45 20.02 20.12
p-value 0.069 0.097 0.123 0.087
Mn
mean 4.71 10.77 3.06 7.55 3.47 6.05 77.83 132.64
st.dev. 2.85 5.47 1.90 5.32 2.07 5.37 29.03 113.01
median 3.93 6.55 2.79 6.29 3.10 3.97 80.66 105.83
p-value 0.039 0.044 0.095 0.019
Co
mean 0.47 0.25 0.43 0.14 0.04 0.04 1.63 2.18
st.dev. 0.21 0.25 0.17 0.10 0.01 0.02 0.71 1.91
median 0.47 0.12 0.43 0.12 0.03 0.03 1.58 1.36
p-value 0.121 0.088 0.444 0.215
Ni
mean 4.64 4.24 4.04 2.58 5.14 3.19 26.67 55.64
st.dev. 2.30 3.16 2.45 2.09 3.81 1.68 11.41 47.75
median 4.18 2.90 3.71 1.37 4.15 2.62 22.28 32.04
p-value 0.321 0.302 0.114 0.065
Cu
mean 949 788 125 109 39.99 30.90 1069 1399
st.dev. 216 256 29 43 21.91 25.93 645 1192
median 953 799 121 94 38.31 22.58 1063 1094
p-value 0.089 0.796 0.111 0.099
Zn
mean 619 461 1625 1318 39.16 27.80 2821 4699
st.dev. 96 219 283 298 18.73 21.82 999 2902
median 620 406 1625 1218 35.63 19.83 3014 3859
p-value 0.041 0.046 0.039 0.021
As
mean 1.54 0.86 1.26 1.03 0.86 0.43 0.92 1.85
st.dev. 0.58 0.84 0.56 0.52 0.78 0.19 0.65 1.85
median 1.51 0.65 1.17 0.91 0.49 0.41 0.70 0.84
p-value 0.051 0.077 0.066 0.063
Se
mean 82.43 46.33 24.94 12.96 8.99 6.16 83.71 200.23
st.dev. 19.30 24.21 8.82 8.06 7.24 3.98 36.61 180.02
median 82.65 37.67 24.67 13.60 5.78 4.99 66.60 146.48
p-value 0.024 0.033 0.102 0.003
Sr
mean 70.62 41.81 34.36 14.57 21.32 14.62 17.32 381.89
st.dev. 11.73 25.41 11.86 11.41 11.48 9.63 10.81 252.87
median 71.53 32.08 32.33 9.22 19.59 11.98 14.32 41.03
p-value 0.018 0.009 0.035 0.001
Cd
mean 0.02 0.31 0.01 0.31 0.26 0.12 6.71 4.63
st.dev. 0.01 0.27 0.003 0.31 0.22 0.07 6.02 4.77
median 0.02 0.25 0.01 0.18 0.18 0.10 3.65 2.75
p-value 0.000 0.005 0.012 0.088
Ce
mean 0.30 0.25 0.28 0.14 0.25 0.25 0.26 1.83
st.dev. 0.20 0.36 0.16 0.12 0.25 0.16 0.24 1.33
median 0.25 0.11 0.25 0.09 0.17 0.07 0.16 0.44
p-value 0.024 0.008 0.011 0.044
Pt
mean 0.03 0.21 0.01 0.02 0.03 0.02 0.02 0.03
st.dev. 0.02 0.09 0.01 0.02 0.03 0.01 0.02 0.02
median 0.02 0.04 0.01 0.01 0.01 0.00 0.01 0.01
p-value 0.002 0.253 0.321 0.353
Pb
mean 4.34 11.79 3.99 8.52 22.85 8.35 49.39 155.29
st.dev. 1.07 4.44 0.89 5.60 20.67 7.87 36.11 120.45
median 4.35 4.27 1.23 4.08 13.67 8.76 24.31 88.16
p-value 0.020 0.025 0.032 0.000
U
mean 0.06 1.52 0.03 1.27 0.02 0.16 0.11 1.13
st.dev. 0.06 0.68 0.02 0.55 0.02 0.09 0.10 0.63
median 0.05 0.12 0.04 0.14 0.01 0.03 0.06 0.21
p-value 0.001 0.000 0.000 0.000
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CSF samples, and that there were no differences for Al, Cu, and Se ratios. These data agree with the results of our 
study. Andrasi et al.18 investigated several metals at the tissue level of glioblastoma patients and they reported no 
significant difference for tissue Cu between malignant and control samples, which is in agreement with the find-
ings of the current study. Furthermore, the higher Sr content in glioblastoma brain tissues reported by Andrasi 
et al.18 is in agreement with the current study. Schrauzer19 reported that Co, Zn, and Se contents were higher in 
CT samples of MBT patients than in HTs. Our results support their findings. Civit et al.2 studied a high-grade 
oligodendroglioma tissue. Although only one sample was analyzed, there is agreement between their study and 
our current study regarding the contents of Cu, Co, As, Se, Mn, and Al and regarding the higher Zn content in 
CT. Recently, higher Zn content in samples of glioblastoma multiforme than in HT was reported by Wandzilak 
et al.20. Lankosz et al.3 showed the elemental profile of glial tissues could be applied to discriminate some types of 
brain tumors. Although relatively few studies have dealt with metal contents in MBTs, clear similarities between 
our current results and those reported previously for essential (Cu, Zn, Mn, Se, and Co) and toxic metals (Al, Sr, 
and As) was found.
Essential metals in the brain. Brain metal homeostasis is achieved through specific transporters within 
the BBB, choroid plexus, hippocampus, and other regions, which can adequately deliver essential trace metals to 
the brain and remove excess metals from it. However, an excess of essential metals, like low levels of toxic metals, 
could induce neurological impairments5.
Copper is essential for normal brain function. The free Cu ion is transported through the BBB into the brain 
parenchyma, where it is utilized and released into the CSF5. Although an increased content of blood Cu has been 
associated with solid tumors, hematological malignancies21,22, and cancer progression (due to its key role in angi-
ogenesis)4, no relationship between altered Cu level and brain cancers has been found. This is in agreement with 
the findings of the current study. The neuroprotective properties of Zn were demonstrated in the study by Jomova 
and Valko4. Due to its role in stabilization of myelin structure, Zn primarily accumulates in the white matter of 
the brain5. According to that study5, the reduced contents of Zn in liquid clinical samples and increased content in 
CTs could indicate the potential of malignant brain cells to withdraw essential Zn from the blood and/or CSF into 
the CT for the stimulation of cerebral tissue growth. Considering that the Cu/Zn ratio has been recommended 
as a suitable diagnostic blood marker for a great number of diseases, including various cancers23, we wanted to 
examine its potential role in the diagnostics of MBTs. The results of this research showed the Cu/Zn ratio has no 
role in discriminating our MBT samples from control samples, an important finding for excluding the Cu/Zn 
ratio from further evaluation.
It was previously reported that Mn mainly accumulated in the choroid plexus when the blood level of Mn 
was maintained at a constant7. Floriańczyk et al.24 mentioned the higher amount of Mn in the blood of MBT 
patients. However, the role of Mn in MBTs is not adequately understood. Our results showed that MBT patients 
had significantly elevated contents of Mn in their serum, CF, CSF and tissue samples, which implicates a role for 
the essential metal Mn in the stimulation of MBTs.
Although brain tissue is Se-deprived, Se deficiency can cause irreversible damage to the CNS5. In the current 
study, no Se deficiency was found in MBT patients. On the contrary, the investigated CTs contained significantly 
elevated Se levels. These results are very interesting, considering that our previous study highlighted the defi-
ciency of Se in the thyroid tissue of the Serbian population25. Furthermore, in the current study, the Se concentra-
tions in analyzed liquid clinical samples of MBT patients were significantly lower than in the CGs, which could 
signify the sequestration of Se into the malignant brain cells for the stimulation of cancer growth.
Effects of toxic metals on brain homeostasis. This study demonstrated that the contents of Al, As, 
Ni, and Cd in CTs of MBT patients were not significantly different than the contents of these metals in the CG. 
Therefore, we suggest Al, As, Ni, and Cd could be eliminated from the point of view of MBT etiology. However, 
the high Pb content in serum, CFs, and CTs deserves further attention. It was reported that Pb, due to its nega-
tive effects on neurotransmitter pathways, could be harmful to brain tissue5. Investigations that considered Pb 
exposure and the risk of brain tumors are contradictory26. A recent investigation reported an increased risk of 
brain cancer with increasing Pb emissions from gasoline8. However, this information is of little importance for 
the Serbian population, since Pb was removed from gasoline over 30 years ago, according to international and 
national guidelines. In another study, no relationship was found between Pb and brain cancers27. According to the 
results obtained in our current study, the significantly elevated contents of Pb in the serum, CF and CT samples 
of MBT patients deserve further investigation.
Although Pb contents were able to discriminate MBT patients’ samples from the control samples, U acts as 
a major cerebral discriminator between samples from the ill and healthy groups. A possible explanation for the 
large U contents in the analyzed samples could be the several radioactive outbreaks that Europe experienced in 
recent decades, while Serbia (a part of the former Federal Republic of Yugoslavia) suffered directly from aerial 
bombardment in 1999. The U-based ammunition that was used during the air attacks on Serbia is the most recent 
source of U pollution released into the Serbian environment28–31. Uranium is primarily introduced into the body 
after inhalation and/or ingestion. Strongly oxidizing uranyl ion (UO22+) in body fluids can form complexes, 
mainly with hydrogen-carbonate, which increases the solubility of U in blood30,32. Several studies reported con-
centrations of U in different types of blood samples. In a neighboring country, Croatia, the concentration of U 
in serum was 0.10–0.72 µg/L32, which is approximately 10-fold higher than the range previously reported in the 
Table 1. The content of metals in serum, cell fraction (CF), cerebrospinal fluid (CSF), healthy tissue (HT) and 
cancerous tissue (CT) samples (ng/g). The differences between groups were examined by Mann-Whitney U-test 
(at significance level 0.05). Statistically significant values are in bold.
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literature (0.014–0.015 µg/L)33. Our previous study showed the healthy Serbian population had 0.03 to 0.20 µg/L 
of U in whole blood samples34. Dodorov et al.35 reported U concentrations of 0.14 to 0.80 µg/L in the blood of 
veterans exposed to depleted U in Gulf War I. Al-Hamzaei et al.36 analyzed whole blood samples from inhabitants 
from several locations that were centers of intensive military activities during Gulf wars. The authors reported a 
significantly higher mean concentration of U in the blood of cancer patients (2.62 ± 0.1 µg/L) compared to the 
CG (1.54 ± 0.1 µg/L). The present research showed the U concentrations in the serum (1.52 ± 0.68 ng/g) and CF 
(1.27 ± 0.55 ng/g) of MBT patients were similar to reported concentrations. The content of U in control and/or 
pathological CSF is unknown. As far as we can ascertain, this is the first study to show the content of U and the 13 
other trace elements in CSF (Table 1).
Although the bones and kidneys are target organs for the manifestation of U toxicity, it was shown that U 
can cross the BBB and accumulate in the brain6,37. Imaging of U in different brain parts was studied by Zoriy et 
al.38. Accumulation of U is not uniform throughout the brain and it was demonstrated to be dose-dependent37. 
Al-Hamzaei et al.36 reported that the increased chemical activity of U could cause DNA mutations, and poten-
tially, cancerogenesis. However, the issue of U toxicity remains unclear.
It is worth noting that all analyzed samples in the current study were collected in the period 2016–2019, and 
that the ICP-MS instrument used in this study cannot provide information on whether depleted U was detected 
Figure 1. Box-plots for analyzed trace metals in the serum (S), cell fraction (CF), cerebrospinal fluid (CSF), 
healthy tissue (HT) and cancerous tissue (CT) samples of patients with malignant brain tumors (MBTs) in 
comparison to control group (CG).
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in our samples, due to the inability of quadrupole (Q) to accurately separate 235U from 238U. However, the high 
U contents in sera, CF, CSF and CT samples from MBT patients and the contents occurring in healthy subjects 
should be further investigated in clinical studies.
For the first time, this study showed that MBT patients had altered profiles of some metals in serum, CF, CSF, 
and CT samples when compared to control samples. Moreover, the higher contents of Mn, Se, and Pb in MBT 
patients could indicate these metals are involved in the pathogenesis of MBTs. However, the most noticeable 
change found was the elevated U content, indicating its considerable role as a major cerebral discriminator of 
the presence/absence of MBTs. The U/Se ratio could be considered as an appropriate blood marker in diagnostic 
MBT evaluation. The results of this research could lead to a better understanding of the roles of essential and 
toxic trace metals in the inadequately understood pathogenesis of MBTs. Furthermore, the obtained results could 
indicate a molecular basis for the pathophysiological changes stemming from the hazardous effects of trace metals 
on brain homeostasis and dysfunction.
Figure 2. Map of Serbia. The shaded fields indicate the place of residence of the individuals as well as the 
potential causes of U exposure. The image was modified according to Stojsaljević et al.34 using Adobe Photoshop 
CS5 (Adobe Systems Incorporated, San Jose, CA, USA).
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Serum CF CSF Brain tissues
Control Tumor Control Tumor Control Tumor Control CT
Cu/Zn
GM 1.51 1.79 0.08 0.08 0.97 1.04 0.32 0.26
P5 0.94 1.03 0.05 0.04 0.49 0.38 0.16 0.10
P25 1.27 1.35 0.06 0.06 0.70 0.90 0.31 0.14
P50 1.50 1.67 0.07 0.07 0.85 1.16 0.37 0.21
P75 1.78 2.27 0.09 0.10 1.33 1.32 0.45 0.49
P95 2.65 3.01 0.12 0.51 2.34 2.03 0.58 0.78
LL-UL 1.40–1.74 1.54–2.28 0.07–0.09 0.05–0.15 0.85–1.36 0.90–1.43 0.26–0.49 0.22–0.47
p-value 0.222 0.339 0.247 0.169
Zn/Mn
GM 149 91 573 195 6.9 7.6 31 36
P5 62 36 241 47 2.2 3.7 17 13
P25 90 64 397 116 3.8 5.2 25 20
P50 140 98 544 224 6.7 7.5 38 39
P75 216 132 720 304 9.0 10.9 40 48
P95 461 194 2465 823 27.2 16.8 44 118
LL-UL 134–222 78–136 483–903 160–329 6.2–13.4 6.1–12 24–41 30–61
p-value 0.033 0.001 0.212 0.189
Zn/Se
GM 7.6 10.2 68 74 5.2 4.5 34 27
P5 4.9 4.7 39 23 1.4 2.3 16 8
P25 5.9 6.7 55 55 2.2 3.1 31 17
P50 7.4 9.8 65 72 7.2 4.2 33 28
P75 10.4 15.8 91 101 9.1 7.4 49 40
P95 12.3 21.3 138 201 12.7 9.3 60 72
LL-UL 7.1–8.9 8.3–15.1 62–82 62–102 5–8.5 3.8–6.6 26–49 24–41
p-value 0.144 0.332 0.412 0.214
Pb/Mn
GM 1.00 0.49 1.37 0.48 2.00 1.18 0.53 0.61
P5 0.29 0.15 0.22 0.06 0.07 0.13 0.18 0.08
P25 0.55 0.29 0.98 0.21 0.31 0.20 0.28 0.25
P50 1.13 0.57 1.52 0.37 4.70 2.50 0.50 1.01
P75 1.63 0.68 1.96 1.52 8.66 3.86 0.86 1.49
P95 2.98 2.26 6.78 2.88 18.99 5.82 1.82 2.28
LL-UL 0.94–1.51 0.37–0.99 1.21–2.43 0.44–1.28 3.56–9.57 1.39–3.67 0.28–1.17 0.65–1.42
p-value 0.048 0.025 0.058 0.236
Pb/Se
GM 0.05 0.05 0.12 0.18 1.40 0.66 0.47 0.41
P5 0.02 0.01 0.05 0.04 0.09 0.09 0.13 0.04
P25 0.04 0.03 0.10 0.09 0.31 0.22 0.24 0.14
P50 0.05 0.04 0.12 0.18 2.28 1.10 0.42 0.58
P75 0.07 0.06 0.15 0.41 3.81 1.59 0.86 1.37
P95 0.09 0.33 0.24 0.88 13.4 3.28 2.45 3.38
LL-UL 0.05–0.06 ≤0.23 0.11–0.15 0.15–0.39 1.6–5.9 0.7–1.67 0.12–1.46 0.48–1.41
p-value 0.269 0.141 0.084 0.222
U/Mn*
GM 9.36 18.41 9.35 16.84 4.32 9.30 1.05 1.73
P5 0.71 4.51 0.93 0.74 1.54 2.15 0.28 0.26
P25 5.74 6.22 5.69 3.75 3.33 3.86 0.36 0.50
P50 10.88 16.68 10.19 17.14 4.56 6.06 0.69 1.49
P75 14.35 29.52 20.22 86.31 5.69 15.82 3.23 4.65
P95 119 197 62.62 296 11.30 169 6.72 30.1
LL-UL 6.6–29 12.4–81 8.8–21.8 23.6–101 3.9–6.3 ≤98.2 0.28–4.1 1.85–10.2
p-value 0.032 0.030 0.025 0.128
U/Se*
GM 0.51 2.42 1.09 6.52 3.01 5.55 0.93 1.16
P5 0.10 0.42 0.19 0.71 1.12 1.01 0.26 0.18
P25 0.32 1.03 0.77 1.70 2.09 1.72 0.33 0.38
P50 0.55 1.62 1.21 5.43 2.72 4.46 0.61 0.94
P75 0.78 7.76 1.93 30.30 3.44 9.81 3.38 4.75
P95 2.97 21.25 3.73 56.43 10.55 98.42 5.11 12.42
LL-UL 0.48–1.03 1.0–12.1 1.08–1.82 6.8–24 2.3–5.8 ≤41.4 0.35–3.30 1.42–5
p-value 0.010 0.001 0.045 0.658
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Material and Methods
Sample collection. The research included 61 patients with MBTs (female/male ratio = 25/36; mean age: 40 
± 4), 51 patients with hydrocephalus (female/male ratio = 24/27; mean age: 47 ± 5), and 61 healthy blood donors 
(female/male ratio = 30/31; mean age: 45 ± 6).
Intravenous blood from blood donors and patients with MBTs was collected in trace metal-free evacuated 
tubes (BD Vacutainer). The collected whole blood (5 mL) from each subject was left for approximately 30 min 
and the obtained serum was separated from the CF after centrifugation (3000 × g). The serum and CF samples 
were immediately frozen at −80 °C. CSF was collected by ventricular puncture during a surgical shunt procedure 
in patients with hydrocephalus. Brain tissues were collected during surgery. Preoperative diagnosis was carried 
out by applying imaging techniques, such as X-ray, computed tomography, and/or magnetic resonance imaging 
(MRI). A definitive diagnosis of MBT was confirmed by two neuropathologists after postoperative histopatholog-
ical analysis of brain tissue. The standard technique for surgical excision of CT included the peritumoral margin 
of normal cerebral tissue. This tissue was collected and considered as HT after the exclusion of tumor by histo-
pathological examination. HT samples we utilized as defined self-controls for each patient’s tumor tissue samples. 
All tumors were classified according to the criteria defined by the World Health Organization (WHO). The fol-
lowing types of MBT were included in the research: 54 glioblastoma multiforme grade IV, three medulloblastoma 
grade III, and four atypical teratoid rhabdoid tumors. All collected samples were stored at −80 °C until analysis.
In order to avoid confounding factors in the distribution of metals, smokers and patients who had other 
malignancies or liver or kidney failure were excluded from this research. Approval was obtained by the Ethics 
Committee of Clinical Centre of Serbia, Belgrade. All patients and blood donors voluntarily participated in this 
research, and written informed consent from all study participants was obtained.
All methods were conducted following relevant guidelines and regulations.
Chemicals, instrumentation and analysis. High grade concentrated nitric acid and hydrogen peroxide 
were supplied by Merck (Darmstadt, Germany). Nitric acid was additionally purified using the Berghof-acid 
purification apparatus-BSB-939-IR. Ultrapure water (resistance of 18.2 MΩ) was obtained by Milli Q Plus System 
(Merck, Darmstadt, Germany). A certified multi-element standard solution containing 22 elements (10 mg/L) 
and an internal standard solution (100 mg/L 7Li, Sc; 20 mg/L Bi, Ga, In, Tb, Y) were supplied by VHG, Manchester, 
UK. Instrumental parameters for ICP-MS were optimized using iCAP Q tuning solution containing 1 µg/L of Ba, 
Bi, Ce, Co, In, Li and U in 2% nitric acid (Thermo Scientific, UK). Standard reference materials (SRMs) of whole 
blood (SERO210105, Level 1, and SERO210305, Level 3) (Seronorm, Sero AS, Norway), and bovine liver (1577c, 
NIST, US) were employed for analytical quality assurance. Samples were digested using a microwave digestion 
system (ETHOS 1, Milestone, Italy).
All elements were quantified by inductively coupled plasma-mass spectrometry, ICP-MS (iCAP Qc, Thermo 
Scientific, UK). Pure argon (99.999%), supplied by Messer (Pančevo, Serbia) was used for plasma formation and disper-
sion of diluted samples. The collision cell of ICP-MS was filled with high purity helium gas (99.999%), also supplied by 
Messer. All measurements on ICP-MS were performed in the optimized interference mode, which is based on kinetic 
energy discrimination. In order to compensate matrix-induced ion signal fluctuations and instrumental drift, a solution 
containing 45Sc at a concentration of 50 µg/L and 71Ga, 89Y, 115In, 159Tb, 208Bi at concentrations of 10 µg/L was equally 
distributed by a second channel of the peristaltic pump in blank, standard solutions, and samples. By applying six cali-
bration solutions in a range from 1 to 500 µg/L, the linearity of the calibration curve for each element was greater than 
0.999. Intra-day precision was estimated by calculating the relative standard deviation (RSD) at three different standard 
concentrations (5, 50 and 100 μg/L) in 6 replicates. Inter-day precision was estimated for the same calibration solutions 
(6 replicates over 6 consecutive days). Intra-day and inter-day RSDs were 2.5% and 3.7%, respectively. The limit of 
detection (LOD) and limit of quantification (LOQ) were determined based on the mean and standard deviation of a 
blank. Three and ten determinations were made with a blank solution (at no concentration in the appropriate matrix) to 
set the LOD and LOQ, respectively. The accuracy of the analytical method was controlled by SRMs. Based on the accu-
racy obtained with SRMs, the following isotopes were selected: 27Al, 55Mn, 59Co, 60Ni, 65Cu, 66Zn, 75As, 82Se, 88Sr, 111Cd, 
142Ce, 194Pt, 208Pb, and 238U. The obtained recovery values for elements in SRMs were in the range of 91.2 to 108.9%.
Microwave digestion of samples. Approximately 0.5 g of sample was transferred into a microwave ves-
sel and the exact weight was measured. All samples were digested at 180 °C in a 4:1 (v/v) mixture of nitric acid 
(65%) and hydrogen peroxide (30%). Microwave digestion was performed according to the following mode of 
operation: 5 min warm-up to 180 °C and hold at 180 °C for an additional 20 min. After a cooling period, digested 
samples were transferred into 25 mL-volumetric flasks and diluted with ultrapure water. The SRMs were firstly 
reconstituted according to the manufacturers’ instructions and further prepared as clinical samples.
Data analysis. Descriptive statistics, Box plots, Chi-squared test, Kolmogorov Smirnov’s test, and Mann 
Whitney U-test were performed using SPSS statistical software (IBM Statistics 20). In all applied statistical 
tests, the significance level was 0.05. According to the recommendations of International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) and the International Union for Pure and Applied Chemistry 
(IUPAC), the ratio between metals was expressed as a percentile (P) in the range of the 5th–95th percentiles, and it 
was calculated as the lower limit (LL) and upper limit (UL) of the 95% confidence interval (CI).
Table 2. The geometric mean (GM), percentiles (P), and the lower limit (LL) and upper limit (UL) of 95% 
confidence intervals for the ratios of metal contents (ng/g) in serum, cell fraction (CF), cerebrospinal fluid (CSF), 
healthy tissue (HT) and cancerous tissue (CT) samples. The differences between groups were examined by Mann-
Whitney U-test (at significance level 0.05). Statistically significant values are in bold. *Results presented in pg/kg.
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